Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM? Academic Article uri icon

abstract

  • Aim: To compare the cost-effectiveness of olaparib versus control treatment in metastatic castration-resistant prostate cancer patients with at least one gene mutation in BRCA1, BRCA2 or ATM from the US payer perspective. Methods: A Markov model was constructed to assess the quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios. Sensitivity analyses and scenario analyses were conducted to explore the impact of uncertainties. Results: The base-case result indicated that, for patients with specific gene mutations, olaparib gained 1.26 QALYs and USD$157,732 total cost. Compared with control treatment, the incremental cost-effectiveness ratio of olaparib was USD$248,248/QALY. The price of olaparib was the most influential parameter. Conclusion: Olaparib is not cost effective in comparison with control treatment in metastatic castration-resistant prostate cancer patients with specific gene mutations.

published proceedings

  • Pharmacogenomics

altmetric score

  • 3.35

author list (cited authors)

  • Li, Y., Lin, S., Zhong, L., Luo, S., Huang, X., Huang, X., ... Weng, X.

citation count

  • 0

complete list of authors

  • Li, Yiyuan||Lin, Shen||Zhong, Lixian||Luo, Shaohong||Huang, Xiaoting||Huang, Xiaojia||Dong, Liangliang||Xu, Xiongwei||Weng, Xiuhua

publication date

  • January 2021